There's So Much Russia Happening Right Now It's

New Post Public Reply Private Reply Replies (0) Message Board

Jun 1, 2017 at 4:57 PM 166

Quote:

There's So Much Russia Happening Right Now

It's essential that we don't lose the plot.

Getty

By Charles P. Pierce

Jun 1, 2017

Well, ever since our last episode of Moscow on the Potomac, we have learned that the president* is thinking about giving the Russians back the pleasure palaces that his predecessor confiscated as punishment for Russian meddling in our election. (We have the quid and we have the quo. We're just investigating the extent of the pro at the moment.)

We also have learned that the attorney general, Jefferson Beauregard Sessions III, conveniently forgot during his sworn testimony before the Senate Judiciary Committee, and in his letter to that committee "correcting" his testimony, that he had yet another meeting with boyar-about-town Sergey Kislyak. In other words, there appears to be mounting evidence that the Attorney General of the United States lied to Congress, which used to be a big deal.

Let's see. Have I missed anything?

Oh yeah, imported nuisance Nigel Farage seems to be on the FBI's radar, which indicates that the investigation is going international with an eye toward tracing the connections between the Russian ratfcking, the role of WikiLeaks founder Julian Assange, and various rightwing candidates of many lands.

And the counterattack is beginning to take shape in the House of Representatives, courtesy of Congressman Devin Nunes, the allegedly recused chairman of the House Intelligence Committee.

Just as the news broke Wednesday that James Comey indeed would be testifying in the Senate about his dealings with the president* on all these matters, it also was revealed that Nunes, acting alone on his authority as chairman, had issued subpoenas related to the "unmasking" of Americans caught up in surveillance during the Obama administration. From McClatchy:

On Wednesday, various news outlets reported that the intelligence committee had subpoenaed three former Obama administration officials to address Nunes' allegations. The reports identified the three as former U.N. Ambassador Samantha Power, former National Security Adviser Susan Rice and former CIA Director John Brennan. But House Intelligence committee staff members would not confirm the reports, and one said whatever subpoenas might have been issued were not part of the committee's Russia probe and had not been approved by the Democrats on the committee.

"If the reports are accurate, subpoenas related to the 'unmasking' issue would have been sent by Chairman Nunes acting separately from the committee's Russia investigation," the senior aide wrote in an email. "This action would have been taken without the minority's agreement. Any prior requests for information would have been undertaken without the minority's knowledge."

It's fairly obvious that this "unmasking" business is going to be the primary mode of distraction employed by the Republicans in various congressional hearings to draw attention away from the slow dance this administration has been doing with the folks in Moscow.

(I think they subpoenaed Susan Rice out of pure conditioned reflex at this point.)

But the general scope of the disaster that is gathering speed in the direction of the White House is becoming clearer. There is virtually nobody in the Trump inner circle who is not compromised in some way by the connections the campaign had with the oligarchs and kleptocrats, and now that seems to be spreading into the Cabinet as well.

The corruption is systemic. What worries me is that it goes in so many directions at this point that the outrage may lose its focus on the simple fact that very effective means were employed to place in the White House an unqualified and vulgar talking yam for the specific purpose of hog-tying the government of the United States. That's the poisonous tree. The rest is all the fruit of it.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Everest Group Faces Major Class Action Deadline Looms

Everest Group's Headaches Multiply as Deadline Approaches Well, here we find a classic case of Wall Street drama—Everest Group, Ltd. (NYSE:EG), a company whose troubles would make any trader weary. As of late, it's caught up in a nasty class-action lawsuit with stakes high enough to raise eyebrows from Broadway to Bayou. Investors in Everest better be tuned in, because...

Tenax Therapeutics Faces Legal Heat After Stock Plunge

Investors' Nerves Tested as Tenax Takes a Nosedive Holy smokes! When a biotech company like Tenax Therapeutics, Inc. (NASDAQ: TENX) detonates like a forgotten fireworks stash, investors have every right to get itchy. Tenax’s shocking announcement that their Phase 3 LEVEL trial for TNX-103 flopped has sparked more than just shareholder anxiety. It’s ignited a...

Adding Fireplaces: Home Comfort or Construction Headache?

Sizing Up the Installation Options Slapping a fireplace into a home sounds more like a pipe dream than a practical project for most folks. But according to fireplace whiz Jimmy Smith down in North Charleston, the times are a-changin'. These days, with advances in technology, homeowners can actually pull it off without collapsing their living room walls. Nitty-Gritty:...

DraftKings Faces Revenue Cutback; Legal Probe Begins

DraftKings' Surprising Turn of Fortune Talk about a gut punch! DraftKings (NASDAQ: DKNG) dropped a bombshell that had investors reeling. They decided to lop off a hefty slice of their revenue guidance, and trust me, those aren't small numbers we’re talking about. On November 6, they yanked their full-year 2026 revenue guidance down to $6.35 billion to $6.55 billion from...

Tenax Sued: Investors Face Class Action Over TNX-103

What Tenax Investors Need to Know Alright, folks, time to pull up a chair and pay attention to what's brewing with Tenax Therapeutics—yeah, we're talking NASDAQ: TENX. The company's head is spinning as it's caught up in a securities class action lawsuit. What's the fuss? The fine print here accuses Tenax of misleading investors about the effectiveness of their product,...

Datavault AI's Turbulent Boardroom Saga Escalates

The Corporate Chess Game at Datavault AI If there's one thing Wall Street hates, it's uncertainty. And boy, does Datavault AI (NASDAQ: DVLT) deliver plenty of it right now. Founder Nathaniel Bradley has lobbed a lawsuit at the board, claiming that Chairman and CFO Brett Moyer orchestrated a coup to oust him without proper board procedures. Talk about drama fit for a soap...

NatGold Pulling NATG From MEXC Amid Security Concerns

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

Muyuan Foods Spotlights Smart Farming at EuroTier 2026

Muyuan Foods Ready to Impress at EuroTier 2026 Let's face it, folks—when you think of game-changers in pig farming, Muyuan Foods Group deserves a nod. They're not just trotting out oinkers left and right; they're steering the whole paddock with innovations in smart pig farming and green development solutions. At EuroTier 2026 in Hanover, Muyuan’s booth—J04 in Hall...

FuelCell Faces Class Action Crunch as Deadline Looms

FuelCell's Legal Storm: What to Know Now You ever get that feeling when your gut knows it all before you even finish reading the headline? Well, buckle up, because FuelCell Energy, Inc. (NASDAQ:FCEL) is staring down a potential class-action train wreck, and they ain't got much track left to skid on before the deadline hits hard on November 10th, 2026. The Crunchy Details...

Invasive Procedures Don't Extend Life in Stable Heart Disease

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...